KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
KBIO was delisted on the 16th of December, 2015.
17 hedge funds and large institutions have $4.45M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 7 closing their positions.
157% more capital invested
Capital invested by funds: $1.73M → $4.45M (+$2.72M)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
21% more funds holding
Funds holding: 14 → 17 (+3)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$522K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$151K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$104K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$60.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$1.02M |
| 2 |
Renaissance Technologies
New York
|
-$278K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$111K |
| 4 |
Bank of New York Mellon
New York
|
-$98K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$58K |
KBIO Hedge Fund Activity: Q4 2015 in Review
17 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q4 2015, worth a combined $4.45M — up 157% from $1.73M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KBIO positions and 7 closed out — a net gain of 3 holders — while 0 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $522K. The largest seller was Primecap Management, exiting entirely with an estimated $1.02M sold.
- 17 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q4 2015, up from 14 in Q3 2015.
- Funds reported $4.45M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q4 2015, up 157% quarter-over-quarter.
- 10 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q4 2015 and 7 closed out, a net change of +3 holders.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q4 2015 was Morgan Stanley, an estimated $522K added.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q4 2015 was Primecap Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q4 2015.